BUSINESSBLOOMBERG
Argenx Soars on Latest Trial Success for Autoimmune Drug Vyvgart
Argenx SE's shares jumped after the European biotech reported a successful trial for its drug Vyvgart. The company reported that this was the latest large, successful trial conducted for the autoimmune drug.
Related Signal
Adjacent reporting
- STAT+: Argenx to buy Forte Biosciences for $2.2B
- French biotech stock soars 31% after new data on experimental medicine
- STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
- STAT+: Amylyx nears pivotal endocrine drug study readout
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
- STAT+: Legend Biotech emerged as a rare market winner